Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inhaled antibodies: Quality and performance considerations
Anthony J. Hickey, Ian E. Stewart
Human Vaccines & Immunotherapeutics (2021) Vol. 18, Iss. 2
Open Access | Times Cited: 24

Showing 24 citing articles:

Designing antibodies as therapeutics
Paul J. Carter, Arvind Rajpal
Cell (2022) Vol. 185, Iss. 15, pp. 2789-2805
Open Access | Times Cited: 146
Recombinant neutralizing secretory IgA antibodies for preventing mucosal acquisition and transmission of SARS-CoV-2
Kathrin Göritzer, Elisabetta Groppelli, Clemens Grünwald‐Gruber, et al.
Molecular Therapy (2024) Vol. 32, Iss. 3, pp. 689-703
Open Access | Times Cited: 11
The (re)emergence of aerosol delivery: Treatment of pulmonary diseases and its clinical challenges
Rosy Ghanem, Raphaëlle Youf, Tanguy Haute, et al.
Journal of Controlled Release (2025) Vol. 379, pp. 421-439
Open Access | Times Cited: 1
Recent progress in drying technologies for improving the stability and delivery efficiency of biopharmaceuticals
Fakhrossadat Emami, Mahsa Keihan Shokooh, Seyed Jamaleddin Mostafavi Yazdi
Journal of Pharmaceutical Investigation (2022) Vol. 53, Iss. 1, pp. 35-57
Open Access | Times Cited: 33
Recent advances in respiratory immunization: A focus on COVID-19 vaccines
Xiyue He, Xiaohong Chen, Hairui Wang, et al.
Journal of Controlled Release (2023) Vol. 355, pp. 655-674
Open Access | Times Cited: 22
Aerosol pulmonary immune engineering
Emma R. Sudduth, Michael Trautmann-Rodriguez, Nicole Gill, et al.
Advanced Drug Delivery Reviews (2023) Vol. 199, pp. 114831-114831
Open Access | Times Cited: 19
Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters
Metin Aksu, Priya Kumar, Thomas Güttler, et al.
Antiviral Research (2023) Vol. 221, pp. 105778-105778
Open Access | Times Cited: 13
The future of inhalation therapy in chronic obstructive pulmonary disease
Mario Cazzola, Josuel Ora, Luigino Calzetta, et al.
Current Research in Pharmacology and Drug Discovery (2022) Vol. 3, pp. 100092-100092
Open Access | Times Cited: 16
Protein Aggregates in Inhaled Biologics: Challenges and Considerations
Mariam Ibrahim, Ian Wallace, Saba Ghazvini, et al.
Journal of Pharmaceutical Sciences (2023) Vol. 112, Iss. 5, pp. 1341-1344
Open Access | Times Cited: 8
Broadly neutralizing humanized SARS-CoV-2 antibody binds to a conserved epitope on Spike and provides antiviral protection through inhalation-based delivery in non-human primates
Paule Hermet, Benoît Delache, Cécile Hérate, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 8, pp. e1011532-e1011532
Open Access | Times Cited: 8
Breath and Beyond: Advances in Nanomedicine for Oral and Intranasal Aerosol Drug Delivery
Simeng Du, Zhiyang Wen, Jinghan Yu, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 12, pp. 1742-1742
Open Access | Times Cited: 3
Novel strategies in systemic and local administration of therapeutic monoclonal antibodies
Monika Prašnikar, Maja Bjelošević Žiberna, Mirjam Gosenca Matjaž, et al.
International Journal of Pharmaceutics (2024) Vol. 667, pp. 124877-124877
Open Access | Times Cited: 2
Long-acting inhaled medicines: Present and future
Chengqian Zhang, Davide D’Angelo, Francesca Buttini, et al.
Advanced Drug Delivery Reviews (2023) Vol. 204, pp. 115146-115146
Open Access | Times Cited: 6
bioTCIs: Middle-to-Macro Biomolecular Targeted Covalent Inhibitors Possessing Both Semi-Permanent Drug Action and Stringent Target Specificity as Potential Antibody Replacements
Jay Yang, Yudai Tabuchi, Riku Katsuki, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3525-3525
Open Access | Times Cited: 5
Barriers for orally inhaled therapeutic antibodies
Thomas Sécher, Nathalie Heuzé-Vourc’h
Expert Opinion on Drug Delivery (2023) Vol. 20, Iss. 8, pp. 1071-1084
Closed Access | Times Cited: 5
Characterization of dry powder inhaler performance through experimental methods
Conor A. Ruzycki, Scott Tavernini, Andrew R. Martin, et al.
Advanced Drug Delivery Reviews (2022) Vol. 189, pp. 114518-114518
Closed Access | Times Cited: 8
Stability Engineering of Recombinant Secretory IgA
Kathrin Göritzer, Richard Strasser, Julian K‐C.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 6856-6856
Open Access | Times Cited: 1
Inhaled IgG1 antibodies: The buffering system is an important driver of stability during mesh-nebulization
Alexie Mayor, Béatrice Thibert, Sylvain Huille, et al.
European Journal of Pharmaceutics and Biopharmaceutics (2022) Vol. 181, pp. 173-182
Closed Access | Times Cited: 5
Enhanced powder dispersion of dual-excipient spray-dried powder formulations of a monoclonal antibody and its fragment for local treatment of severe asthma
Harry W. Pan, Jinlin Guo, Lingqiao Zhu, et al.
International Journal of Pharmaceutics (2023) Vol. 644, pp. 123272-123272
Open Access | Times Cited: 2
Strategies for overcoming the biological barriers associated with the administration of inhaled monoclonal antibodies for lung diseases
Maria Gabriella Matera, Luigino Calzetta, Barbara Rinaldi, et al.
Expert Opinion on Drug Delivery (2023) Vol. 20, Iss. 8, pp. 1085-1095
Closed Access | Times Cited: 2
A breath of fresh air: inhaled antibodies to combat respiratory infectious diseases - a clinical trial overview
Noémie Alphonse, Thomas Sécher, Nathalie Heuzé-Vourc’h
Expert Opinion on Drug Delivery (2024)
Closed Access
Pulmonary Delivery of Antibody for the Treatment of Respiratory Diseases
Thomas Sécher, Nathalie Heuzé-Vourc’h
AAPS introductions in the pharmaceutical sciences (2023), pp. 21-51
Closed Access | Times Cited: 1
Impact of protein aggregation on the immunogenicity of a human monoclonal antibody following pulmonary administration in mice
Sohaib Mahri, Céline Cassiers, Sandra Gracin, et al.
International Journal of Pharmaceutics (2024) Vol. 667, pp. 124880-124880
Closed Access
Special focus issue: passive immunization
Larry Zeitlin, Richard A. Cone
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 2
Open Access
Page 1

Scroll to top